12:00 AM
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GMI-1070: Completed Phase II enrollment

GlycoMimetics completed enrollment of 76 sickle cell disease patients ages 12-65 years who are experiencing vaso-occlusive crisis in a double-blind, placebo-controlled, North American Phase II trial evaluating twice-daily IV GMI-1070. The product has Fast Track and Orphan Drug...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >